NCT07169279RECRUITINGanonymous

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

Sponsor

Source record

QED Therapeutics, a BridgeBio company

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

Related intelligence directories

Indication directory: Achondroplasia Modality directory: small molecule Target directory: Infigratinib is provided as a single dose of minitablets for oral administration

Source & freshness

Source record

NCT ID

NCT07169279

Original source

ClinicalTrials.gov

Source last updated

Jun 17, 2026

Ingested at

Jun 20, 2026

Internal sync

Jun 20, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07169279

Title

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

Sponsor

QED Therapeutics, a BridgeBio company

Status

RECRUITING

Phase

PHASE2

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Target normalized

Interventions

Public preview

Source record

This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT07169279

Status

RECRUITING

Phase

PHASE2

Sponsor

QED Therapeutics, a BridgeBio company

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 17, 2026

Internal syncJun 20, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07169279

Indication

Achondroplasia

Modality

small molecule

Target

Intervention

Source record